Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Genetics Generation Advancement Quick Ratio?
Genetics Generation AdvancementROCO:4160 -1.20%70 Quick Ratio is 2.74 as of Dec. 2025, which is 15% below its 10-year median of 3.22. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks better than 66.2% on this metric.
Genetics Generation Advancement has a quick ratio of 2.74. It generally indicates good short-term financial strength.
The historical rank and industry rank for Genetics Generation Advancement's Quick Ratio or its related term are showing as below:
ROCO:4160'
s Quick Ratio Range Over the Past 10 Years
Min: 2.73 Med: 3.22 Max: 4.33
Current: 2.74
During the past 13 years, Genetics Generation Advancement's highest Quick Ratio was 4.33. The lowest was 2.73. And the median was 3.22.
ROCO:4160's Quick Ratio is ranked better than 66.2% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.77
vs ROCO:4160: 2.74
Genetics Generation Advancement (ROCO:4160) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Genetics Generation Advancement Quick Ratio Related Terms
Genetics Generation Advancement Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Quick Ratio falls into.
Genetics Generation Advancement Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) has a Quick Ratio of 2.74 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Genetics Generation Advancement and its competitors. This is 15% below median its historical median of 3.22. Over the past decade, Genetics Generation Advancement's Quick Ratio has ranged from 2.73 to 4.33. According to the industry distribution chart, Genetics Generation Advancement ranks #72 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 33.8%.
Is Genetics Generation Advancement's Quick Ratio too high?
Genetics Generation Advancement's current Quick Ratio of 2.74 is 15% below median its 10-year median of 3.22. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 4.33. The Medical Diagnostics & Research industry median Quick Ratio is 1.77. Genetics Generation Advancement's value of 2.74 is 54.8% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #72 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #72 out of 213 companies for Quick Ratio. This puts Genetics Generation Advancement in the upper half of its industry. The industry median Quick Ratio is 1.77. Genetics Generation Advancement's value of 2.74 is 54.8% above this benchmark. Historically, Genetics Generation Advancement's own Quick Ratio has ranged from 2.73 to 4.33 over the past decade. While the company's 10-year median is 3.22 vs. the industry median of 1.77, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.77, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Quick Ratio of 2.74 is 54.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Quick Ratio is 2.74, which is 15% below median its own 10-year median of 3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current Quick Ratio is 2.74, which is 15% below median its 10-year median of 3.22 and 54.8% above the Medical Diagnostics & Research industry median of 1.77. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Quick Ratio is 2.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Quick Ratio: 2.74 (15% below median its 10-year median of 3.22)
GF Value™: NT$51.35 vs. price of NT$41.15 (19.9% below fair value)
Industry Position: 54.8% above the Medical Diagnostics & Research median (#72 of 213)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
